Seiji Fujigaki1, Shin Nishiumi1, Takashi Kobayashi1, Makoto Suzuki1, Takao Iemoto1, Takashi Kojima2, Yoshinori Ito3, Hiroyuki Daiko4, Ken Kato5, Hirokazu Shouji5, Kazufumi Honda6, Takeshi Azuma1, Masaru Yoshida1,7,8. 1. Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Hyogo, Japan. 2. Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan. 3. Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan. 4. Department of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan. 5. Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. 6. Department of Biomarkers for Early Detection of Cancer, National Cancer Center Research Institute, Tokyo, Japan. 7. Division of Metabolomics Research, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan. 8. AMED-CREST, AMED, Kobe, Japan.
Abstract
AIM: To identify the serum metabolomics signature that is correlated with the chemoradiosensitivity of esophageal squamous cell carcinoma (ESCC). MATERIALS & METHODS: Untargeted and targeted metabolomics analysis of serum samples from 26 ESCC patients, which were collected before the neoadjuvant chemoradiotherapy, was performed. RESULTS: On receiving the results of untargeted metabolomics analysis, we performed the targeted metabolomics analysis of the six metabolites (arabitol, betaine, glycine, L-serine, L-arginine and L-aspartate). The serum levels of the four metabolites (arabitol, glycine, L-serine and L-arginine) were significantly lower in the patients who achieved pathological complete response with neoadjuvant chemoradiotherapy compared with the patients who did not achieve pathological complete response (p = 0.0086, 0.0345, 0.0106 and 0.0373, respectively). CONCLUSION: The serum levels of metabolites might be useful for predicting the chemoradiosensitivity of ESCC patients.
AIM: To identify the serum metabolomics signature that is correlated with the chemoradiosensitivity of esophageal squamous cell carcinoma (ESCC). MATERIALS & METHODS: Untargeted and targeted metabolomics analysis of serum samples from 26 ESCC patients, which were collected before the neoadjuvant chemoradiotherapy, was performed. RESULTS: On receiving the results of untargeted metabolomics analysis, we performed the targeted metabolomics analysis of the six metabolites (arabitol, betaine, glycine, L-serine, L-arginine and L-aspartate). The serum levels of the four metabolites (arabitol, glycine, L-serine and L-arginine) were significantly lower in the patients who achieved pathological complete response with neoadjuvant chemoradiotherapy compared with the patients who did not achieve pathological complete response (p = 0.0086, 0.0345, 0.0106 and 0.0373, respectively). CONCLUSION: The serum levels of metabolites might be useful for predicting the chemoradiosensitivity of ESCC patients.